Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 122

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 122
---
 tax losses. Our Israeli subsidiary pays income taxes in Israel in connection with its costs plus agreement with the Company. Liquidity and Capital Resources As of October 31, 2024, we had cash and cash equivalents on hand of $6,573,813 and a positive working capital of $2,956,793, compared to $5,427,739 and positive working capital of $824,760 as of October 31, 2023, respectively. As of July 31, 2025, we had cash and cash equivalents on hand of $3,495,338 and a positive working capital of $918,215, compared to $7,679,648 and positive working capital of $3,319,891 as of July 31, 2024, respectively. We may have capital requirements in excess of its currently available resources. In the event our plans change, our assumptions change or prove inaccurate, or our capital resources in addition to projected cash flow, if any, prove to be insufficient to fund operations, we may be required to seek additional financing. There can be no assurance that we will have sufficient financing to meet its future capital requirements or that additional financing will be available on terms acceptable to us in the future. 75 As of October 31, 2024 and July 31, 2025, we had accounts payable and accrued liabilities of $526,056 and $646,919, respectively. In January 2024, we completed a public offering of our common shares and warrants to purchase our common shares for gross proceeds of $2.4 million. These funds will be used to fund the Company in the near term. As previously announced, on September 17, 2025, we entered into the SPAs with the CLA Investors pursuant to which we shall issue and sell, from time to time, Promissory Notes in the aggregate principal amount of up to $10,000,000. As of the date hereof, we have issued Promissory Notes in the aggregate principal amount of $2.5 million, of which an aggregate of $2.2 million of outstanding amounts due under the Promissory Notes were converted into 4,135,000 common shares. On November 13, 2025, we entered into a securities purchase agreement with investors for the purchase and sale of (i) 958,222 common shares, and (ii) pre-funded warrants to purchase up to 2,984,146 common shares, in a registered direct offering